← All Prokidney CORP filings

Prokidney CORP Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
PROK
Prokidney CORP
SCHEDULE: Morgan Stanley Reduces Stake in ProKidney Corp.
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than five percent of ProKidney Corp.'s Class A Common Stock.
NASDAQ
PROK
Prokidney CORP
SCHEDULE: Morgan Stanley Discloses 6.0% Stake in PROKIDNEY CORP.
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a 6.0% beneficial ownership stake in PROKIDNEY CORP.'s Class A Common Stock.
NASDAQ
PROK
Prokidney CORP
SCHEDULE: Morgan Stanley Cuts PROKIDNEY Stake Below 5%
Morgan Stanley and its investment management arm have reduced their beneficial ownership in PROKIDNEY CORP. to below the 5% reporting threshold.
NASDAQ
PROK
Prokidney CORP
SCHEDULE 13G/A: BlackRock Amends Stake in PROKIDNEY CORP, Holding 1.4% of Class A Stock
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% of PROKIDNEY CORP's Class A Stock as of June 30, 2025.
NASDAQ
PROK
Prokidney CORP
SCHEDULE 13G/A: Morgan Stanley Discloses 7.8% Stake in PROKIDNEY CORP. Through Latest SEC Filing
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a 7.8% beneficial ownership stake in PROKIDNEY CORP. as of March 31, 2025, according to an amended Schedule 13G filing.